Literature DB >> 17222213

The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Mahmoud R Hussein1, Sherifa A Hamed, Mohammed G Mostafa, Eman E Abu-Dief, Nageh Fouly Kamel, Mahmoud R Kandil.   

Abstract

Various clinical trials have documented the therapeutic benefit of glucocorticoids (GCs) in enhancing muscle strength and slowing disease progression of Duchenne and Becker muscular dystrophies (DMD/BMD). We hypothesized that GCs may have relevance to the differential anti-inflammatory effect on mononuclear inflammatory cells (MICs) and Dendritic cells (DCs) infiltrating the dystrophic muscles. In this prospective study, two muscle biopsies were obtained (before and after 6-month prednisone therapy) from 30 patients with dystrophies (DMD = 18; BMD = 6; and limb girdle muscular dystrophies (LGMD) = 6). MICs and DCs infiltrating the muscles were examined using mouse monoclonal antibodies and immunoperoxidase staining methods. Muscle strength was evaluated monthly by manual testing, motor ability and timed tests. Prednisone therapy was associated with: (i) functional improvement of overall motor disability, in upper limbs of DMD (P < 0.001) and BMD (P < 0.01) and lower limbs of DMD (P < 0.001) and BMD (P < 0.05); (ii) histological improvement such as fibre size variation (DMD, P < 0.01; BMD, P < 0.05), internalization of nuclei (DMD, P < 0.05), degeneration and necrosis (DMD and BMD, P < 0.01), regeneration (DMD, P < 0.001; BMD, P < 0.01) and endomysial connective tissue proliferation (DMD, P < 0.01; BMD, P < 0.05) and (iii) reduction of total MICs (P < 0.01) and DCs (P < 0.01). There was a positive correlation between the degree of improvement in overall motor disability and reduction of DCs numbers (In upper limbs; r = 0.638, P < 0.01 for DMD and r = 0.725, P < 0.01 for BMD, in Lower limbs; r = 0.547, P < 0.05 for DMD and r = 0.576, P < 0.05 for BMD). Such improvements and changes of MICs/DCs were absent in LGMD. In DMD/BMD, prednisone therapeutic effect was associated with reduced MICs and DCs numbers. Whether this therapeutic effect reflects targeting of the deleterious immune response produced by these cells mandates further investigations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17222213      PMCID: PMC2517389          DOI: 10.1111/j.1365-2613.2006.00470.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  62 in total

1.  Factors inducing mast cell accumulation in skeletal muscle.

Authors:  J P Lefaucheur; B Gjata; A Sebille
Journal:  Neuropathol Appl Neurobiol       Date:  1996-06       Impact factor: 8.090

2.  Automated sequence screening of the entire dystrophin cDNA in Duchenne dystrophy: point mutation detection.

Authors:  Sherifa Ahmed Hamed; Eric P Hoffman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-01-05       Impact factor: 3.568

3.  Dexamethasone suppressed gene expression and production of interleukin-10 by human peripheral blood mononuclear cells and monocytes.

Authors:  T Fushimi; H Okayama; T Seki; S Shimura; K Shirato
Journal:  Int Arch Allergy Immunol       Date:  1997-01       Impact factor: 2.749

4.  The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities.

Authors:  K M Bushby; D Gardner-Medwin; L V Nicholson; M A Johnson; I D Haggerty; N J Cleghorn; J B Harris; S S Bhattacharya
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

5.  Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy.

Authors:  R M McDouall; M J Dunn; V Dubowitz
Journal:  J Neurol Sci       Date:  1990-11       Impact factor: 3.181

6.  Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls.

Authors:  I Lundberg; J M Brengman; A G Engel
Journal:  J Neuroimmunol       Date:  1995-12       Impact factor: 3.478

7.  Dystrophin or a "related protein" in Duchenne muscular dystrophy?

Authors:  L V Nicholson; M A Johnson; K Davison; E O'Donnell; G Falkous; M Barron; J B Harris
Journal:  Acta Neurol Scand       Date:  1992-07       Impact factor: 3.209

8.  Steroids in Duchenne muscular dystrophy--deflazacort trial.

Authors:  L E Mesa; A L Dubrovsky; J Corderi; P Marco; D Flores
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

9.  Inhibition by glucocorticoids of the formation of interleukin-1 alpha, interleukin-1 beta, and interleukin-6: mediation by decreased mRNA stability.

Authors:  Y Amano; S W Lee; A C Allison
Journal:  Mol Pharmacol       Date:  1993-02       Impact factor: 4.436

10.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

View more
  17 in total

1.  Reduction of dendritic cells by granulocyte and monocyte adsorption apheresis in patients with ulcerative colitis.

Authors:  Grit Waitz; Sebastian Petermann; Stefan Liebe; Joerg Emmrich; Wolfgang Ramlow
Journal:  Dig Dis Sci       Date:  2008-02-06       Impact factor: 3.199

2.  Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.

Authors:  Debra A O'Leary; Orzala Sharif; Paul Anderson; Buu Tu; Genevieve Welch; Yingyao Zhou; Jeremy S Caldwell; Ingo H Engels; Achim Brinker
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

3.  Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.

Authors:  Maria C Vila; James S Novak; Margaret Benny Klimek; Ning Li; Melissa Morales; Alexander G Fritz; Katie Edwards; Jessica F Boehler; Marshall W Hogarth; Travis B Kinder; Aiping Zhang; Davi Mazala; Alyson A Fiorillo; Bonnie Douglas; Yi-Wen Chen; John van den Anker; Qi L Lu; Yetrib Hathout; Eric P Hoffman; Terence A Partridge; Kanneboyina Nagaraju
Journal:  J Pathol       Date:  2019-04-16       Impact factor: 7.996

4.  Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy.

Authors:  Mattia Quattrocelli; Isabella M Salamone; Patrick G Page; James L Warner; Alexis R Demonbreun; Elizabeth M McNally
Journal:  Am J Pathol       Date:  2017-08-18       Impact factor: 4.307

5.  Effect of Ibuprofen on Skeletal Muscle of Dysferlin-Null Mice.

Authors:  Alyssa F Collier; Jessica Gumerson; Kimmo Lehtimäki; Jukka Puoliväli; Jace W Jones; Maureen A Kane; Sankeerth Manne; Andrea O'Neill; Hillarie P Windish; Toni Ahtoniemi; Bradley A Williams; Douglas E Albrecht; Robert J Bloch
Journal:  J Pharmacol Exp Ther       Date:  2017-12-28       Impact factor: 4.030

Review 6.  Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention.

Authors:  Nicholas P Evans; Sarah A Misyak; John L Robertson; Josep Bassaganya-Riera; Robert W Grange
Journal:  PM R       Date:  2009-08       Impact factor: 2.298

7.  Effects of prednisolone on skeletal muscle contractility in mdx mice.

Authors:  Kristen A Baltgalvis; Jarrod A Call; Jason B Nikas; Dawn A Lowe
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

8.  The immune system in Duchenne muscular dystrophy: Friend or foe.

Authors:  S Armando Villalta; Amy S Rosenberg; Jeffrey A Bluestone
Journal:  Rare Dis       Date:  2015-02-23

9.  Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents.

Authors:  Steve D Wilton; Sue Fletcher
Journal:  Appl Clin Genet       Date:  2011-03-10

Review 10.  Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy.

Authors:  Boel De Paepe; Jan L De Bleecker
Journal:  Mediators Inflamm       Date:  2013-11-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.